SIBN logo

SI-BONE Inc. (SIBN)

$23.41

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SIBN

Market cap

$1.06B

EPS

-0.31

P/E ratio

--

Price to sales

4.06

Dividend yield

--

Beta

0.639482

Price on SIBN

Previous close

$23.44

Today's open

$23.37

Day's range

$23.09 - $23.67

52 week range

$11.48 - $25.92

Profile about SIBN

CEO

Laura A. Francis

Employees

376

Headquarters

San Jose, CA

Exchange

NASDAQ Global Market

Shares outstanding

45113087

Issue type

Common Stock

SIBN industries and sectors

Healthcare

Medical Equipment & Supplies

News on SIBN

Are You Looking for a Top Momentum Pick? Why Si-Bone (SIBN) is a Great Choice

Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.

news source

Zacks Investment Research • Nov 12, 2026

news preview

SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript

SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript

news source

Seeking Alpha • Nov 11, 2026

news preview

SiBone (SIBN) Hit a 52 Week High, Can the Run Continue?

Si-Bone (SIBN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

news source

Zacks Investment Research • Nov 5, 2026

news preview

SiBone Q3 Earnings Call Highlights

SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building on momentum across its sacroiliac joint, complex spinal fusion and trauma offerings, while preparing for a broader launch of its newly cleared iFuse Granite Onyx platform.

news source

MarketBeat • Nov 3, 2026

news preview

SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance

Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million, representing growth of 14.5%   U.S. revenue of $52.8 million, representing growth of 13.9% Gross margin of 79.3%   Net loss of $3.6 million, representing an improvement of 20.7%   Positive adjusted EBITDA of $3.0 million, representing an improvement of 32.4% Positive cash from operations of $5.9 million, representing an improvement of 154.4% $146.3 million in cash and equivalents Recent Operational Highlights (any comparisons are to the prior year period) 1,770 active U.S. physicians, representing growth of ~16%       In September, received 510(k) clearance for iFuse Granite Onyx, a FDA breakthrough device targeting failures in spine fusion procedures, with an estimated total addressable market of ~$1.5 billion annually In October, new MS-DRGs took effect for complex spinal fusion procedures incorporating iFuse Bedrock Granite, increasing average hospital inpatient payments by up to ~$50,000 per qualifying procedure SAN JOSE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.

news source

Zacks Investment Research • Nov 2, 2026

news preview

SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026

SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming UBS Global Healthcare Conference in Palm Beach Gardens, FL. Management will be hosting a fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.

news source

GlobeNewsWire • Oct 29, 2026

news preview

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the third quarter of 2026 after market close on Monday, November 2, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

news source

GlobeNewsWire • Oct 19, 2026

news preview

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone

news source

GlobeNewsWire • Sep 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in SI-BONE Inc.

Open an M1 investment account to buy and sell SI-BONE Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SIBN on M1